NCT03650491 is a Phase 1 clinical trial of FOR46 in Multiple Myeloma, sponsored by Fortis Therapeutics, Inc..

Who is sponsoring NCT03650491?

NCT03650491 is sponsored by Fortis Therapeutics, Inc..

What drugs are being tested in NCT03650491?

Interventions in NCT03650491: FOR46.

What condition does NCT03650491 study?

NCT03650491 studies Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission.

Is NCT03650491 still recruiting?

NCT03650491 is currently completed. Last updated 27 July 2022.

Last reviewed 2022-07-27 · How we verify

NCT03650491

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Completed Phase 1 Last updated 27 July 2022

What this trial tests

Phase 1 trial testing FOR46 in Multiple Myeloma in 31 participants. Completed in 31 January 2022.

Timeline

3 April 2019

Primary endpoint
31 January 2022

31 January 2022

Quick facts

Lead sponsor	Fortis Therapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	3 April 2019
Primary completion	31 January 2022
Estimated completion	31 January 2022
Sites	7 locations across United States

Drugs / interventions tested

FOR46 — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →
Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Multiple Myeloma With Failed Remission — all drugs for Multiple Myeloma With Failed Remission →

Sponsor

Fortis Therapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma or Multiple Myeloma in Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. · · 2020 · cited 283× · PMID 33081383 · DOI 10.3390/molecules25204764
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Multiple Myeloma Therapy: Emerging Trends and Challenges.
Dima D, Jiang D, Singh DJ, Hasipek M, et al · · 2022 · cited 51× · PMID 36077618 · DOI 10.3390/cancers14174082
Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Bruins WSC, Zweegman S, Mutis T, van de Donk NWCJ. · · 2020 · cited 42× · PMID 32636838 · DOI 10.3389/fimmu.2020.01155
Bispecifics, trispecifics, and other novel immune treatments in myeloma.
Lancman G, Richter J, Chari A. · · 2020 · cited 41× · PMID 33275733 · DOI 10.1182/hematology.2020000110
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
Davis LN, Sherbenou DW. · · 2021 · cited 38× · PMID 33918370 · DOI 10.3390/cancers13071686
CD46 and Oncologic Interactions: Friendly Fire against Cancer.
Elvington M, Liszewski MK, Atkinson JP. · · 2020 · cited 28× · PMID 33147799 · DOI 10.3390/antib9040059
Myeloma: next generation immunotherapy.
Cohen AD. · · 2019 · cited 22× · PMID 31808859 · DOI 10.1182/hematology.2019000068

Verify or expand the search:

Other trials of FOR46

Trials testing the same drug.

NCT05011188 — FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer · Phase 1, PHASE2 · active not recruiting
NCT03575819 — A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Phase 1 · completed

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Fortis Therapeutics, Inc. trials

Trials by the same sponsor.

NCT03575819 — A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03650491 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fortis Therapeutics, Inc.
Last refreshed: 27 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03650491.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing